Matica Biotechnology, a US subsidiary of CHA Biotech, has appointed Laura Parks as EVP of commercial operations and Heather Sugrue as VP of alliance management to enhance its cell and gene therapy contract manufacturing capabilities.
Matica Biotechnology, a U.S. subsidiary of CHA Biotech, is aiming to capitalize on the growing market of cell and gene therapies by offering a contract manufacturing and development service for the drug makers.
Matica Biotechnology, a wholly-owned subsidiary of CHA Biotech, celebrated the completion of a cell and gene therapy manufacturing facility in College Station, Texas, Tuesday.
Korea JoongAng Daily Sitemap